Ouro Fino Saúde Animal Participações S.A (OFSA3) - Net Assets
Based on the latest financial reports, Ouro Fino Saúde Animal Participações S.A (OFSA3) has net assets worth R$796.86 Million BRL (≈ $156.36 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (R$1.57 Billion ≈ $307.24 Million USD) and total liabilities (R$768.97 Million ≈ $150.88 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check OFSA3 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | R$796.86 Million |
| % of Total Assets | 50.89% |
| Annual Growth Rate | 11.32% |
| 5-Year Change | 24.23% |
| 10-Year Change | 111.74% |
| Growth Volatility | 13.95 |
Ouro Fino Saúde Animal Participações S.A - Net Assets Trend (2011–2025)
This chart illustrates how Ouro Fino Saúde Animal Participações S.A's net assets have evolved over time, based on quarterly financial data. Also explore how large is Ouro Fino Saúde Animal Participações S.A's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Ouro Fino Saúde Animal Participações S.A (2011–2025)
The table below shows the annual net assets of Ouro Fino Saúde Animal Participações S.A from 2011 to 2025. For live valuation and market cap data, see Ouro Fino Saúde Animal Participações S.A (OFSA3) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | R$796.86 Million ≈ $156.36 Million |
+5.35% |
| 2024-12-31 | R$756.40 Million ≈ $148.42 Million |
+9.72% |
| 2023-12-31 | R$689.39 Million ≈ $135.27 Million |
-6.33% |
| 2022-12-31 | R$735.95 Million ≈ $144.41 Million |
+14.73% |
| 2021-12-31 | R$641.45 Million ≈ $125.86 Million |
+14.38% |
| 2020-12-31 | R$560.78 Million ≈ $110.03 Million |
+13.88% |
| 2019-12-31 | R$492.45 Million ≈ $96.63 Million |
+8.01% |
| 2018-12-31 | R$455.94 Million ≈ $89.46 Million |
+12.33% |
| 2017-12-31 | R$405.88 Million ≈ $79.64 Million |
+7.85% |
| 2016-12-31 | R$376.33 Million ≈ $73.84 Million |
-1.05% |
| 2015-12-31 | R$380.31 Million ≈ $74.62 Million |
+15.19% |
| 2014-12-31 | R$330.16 Million ≈ $64.78 Million |
+57.65% |
| 2013-12-31 | R$209.42 Million ≈ $41.09 Million |
+7.49% |
| 2012-12-31 | R$194.84 Million ≈ $38.23 Million |
+9.80% |
| 2011-12-31 | R$177.44 Million ≈ $34.82 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Ouro Fino Saúde Animal Participações S.A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | R$796.84 Million | 100.00% |
| Total Equity | R$796.84 Million | 100.00% |
Ouro Fino Saúde Animal Participações S.A Competitors by Market Cap
The table below lists competitors of Ouro Fino Saúde Animal Participações S.A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Aldebaran Resources Inc
V:ALDE
|
$332.39 Million |
|
Home Center Holdings Co.Ltd
KQ:060560
|
$332.49 Million |
|
Guangzheng Group Co Ltd
SHE:002524
|
$332.55 Million |
|
US Century Bank
NASDAQ:USCB
|
$332.65 Million |
|
Yeal Electric Co.Ltd
SHE:300923
|
$332.28 Million |
|
Esso (Thailand) Public Company Limited
BK:BSRC
|
$332.25 Million |
|
DUKSAN TECHOPIA Co.Ltd
KQ:317330
|
$332.23 Million |
|
Lowland Investment Co
LSE:LWI
|
$332.16 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Ouro Fino Saúde Animal Participações S.A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 756,398,000 to 796,836,000, a change of 40,438,000 (5.3%).
- Net income of 222,311,000 contributed positively to equity growth.
- Dividend payments of 35,000,000 reduced retained earnings.
- Share repurchases of 120,134,000 reduced equity.
- Other factors decreased equity by 26,739,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | R$222.31 Million | +27.9% |
| Dividends Paid | R$35.00 Million | -4.39% |
| Share Repurchases | R$120.13 Million | -15.08% |
| Other Changes | R$-26.74 Million | -3.36% |
| Total Change | R$- | 5.35% |
Book Value vs Market Value Analysis
This analysis compares Ouro Fino Saúde Animal Participações S.A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.13x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 4.52x to 2.13x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | R$6.98 | R$31.50 | x |
| 2017-12-31 | R$7.52 | R$31.50 | x |
| 2018-12-31 | R$8.45 | R$31.50 | x |
| 2019-12-31 | R$9.13 | R$31.50 | x |
| 2020-12-31 | R$10.39 | R$31.50 | x |
| 2021-12-31 | R$11.93 | R$31.50 | x |
| 2022-12-31 | R$13.64 | R$31.50 | x |
| 2023-12-31 | R$12.82 | R$31.50 | x |
| 2024-12-31 | R$14.07 | R$31.50 | x |
| 2025-12-31 | R$14.82 | R$31.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Ouro Fino Saúde Animal Participações S.A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 27.90%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 18.15%
- • Asset Turnover: 0.78x
- • Equity Multiplier: 1.97x
- Recent ROE (27.90%) is above the historical average (20.50%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 15.52% | 15.64% | 0.52x | 1.90x | R$18.20 Million |
| 2015 | 18.20% | 12.96% | 0.77x | 1.82x | R$31.17 Million |
| 2016 | -1.38% | -1.14% | 0.59x | 2.06x | R$-42.84 Million |
| 2017 | 9.39% | 7.54% | 0.62x | 2.00x | R$-2.48 Million |
| 2018 | 15.10% | 11.68% | 0.70x | 1.86x | R$23.25 Million |
| 2019 | 9.40% | 7.47% | 0.71x | 1.77x | R$-2.97 Million |
| 2020 | 16.00% | 12.29% | 0.66x | 1.97x | R$33.64 Million |
| 2021 | 17.77% | 12.59% | 0.76x | 1.86x | R$49.82 Million |
| 2022 | 17.75% | 12.55% | 0.77x | 1.83x | R$57.07 Million |
| 2023 | -7.25% | -5.30% | 0.74x | 1.86x | R$-118.91 Million |
| 2024 | 107.67% | 79.47% | 0.74x | 1.83x | R$738.75 Million |
| 2025 | 27.90% | 18.15% | 0.78x | 1.97x | R$142.63 Million |
Industry Comparison
This section compares Ouro Fino Saúde Animal Participações S.A's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $10,655,441,000
- Average return on equity (ROE) among peers: 15.92%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Ouro Fino Saúde Animal Participações S.A (OFSA3) | R$796.86 Million | 15.52% | 0.96x | $332.33 Million |
| Hypera S.A (HYPE3) | $10.66 Billion | 15.92% | 1.23x | $2.83 Billion |
About Ouro Fino Saúde Animal Participações S.A
Ouro Fino Saúde Animal Participações S.A., together with its subsidiaries, engages in the development, production, and sale of veterinary drugs, vaccines, and other products for production and companion animals primarily in Brazil. The company operates through three segments: Production Animals; Companion Animals; and International Operations. It manufactures and trades in medicines, including an… Read more